Back to News
Market Impact: 0.2
ProMIS Names Commercial Chief; PMN310 Data Due Q1 2027; Stock Down
Source: Nasdaq
Management & GovernanceHealthcare & Biotech
ProMIS Neurosciences appointed Ivana Rubino, Ph.D., as Chief Commercial Officer. The company cited her more than 15 years of experience in Alzheimer's disease, neuroscience, clinical development, medical affairs and commercialization; the article excerpt provides no further details on the appointment or its financial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
PMN0.35
More News
- Dutch Government Plans to Cut ABN Amro Stake to 10.5% From 20.7%
- Paramount's hard-fought takeover of Warner Bros. Discovery closes Tuesday. Here's how we got here
- Paramount Closes Warner Merger in Historic Hollywood Deal
- CNN, CBS News now under one roof as Paramount-Warner Bros merger closes
- Skydance will combine HBO Max and Paramount+ into a single streaming service
- Anduril lands $2.9 billion Navy submarine shipyard contract days after CEO joins Pentagon weapons group
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Sector Analysis, Improvements on Research Data, and Performance Enhancements
- Choosing an AI Copilot for Equity Research